Skip to main content
main-content

2022 Genitourinary Cancers Symposium

News and expert insight from the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Sympsosium

ASCO GU 2022 highlights

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Mapping the impact of COVID-19 on genitourinary cancers

Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic.

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Support for continuing enzalutamide after mCRPC progression

Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant prostate cancer in the context of the current treatment landscape, and outlines unanswered questions.

20-02-2022 | ASCO GU 2022 | Conference coverage | Video

Olaparib plus abiraterone could be a new first-line treatment option for mCRPC

Fred Saad provides an overview of the PROpel study of olaparib plus abiraterone acetate for the first-line treatment of metastatic castration-resistant prostate cancer, and outlines the next steps.

  • » This activity is intended for US healthcare providers and was made possible by educational funding provided by Astellas Pharma.

Expert video interviews

08-03-2022 | ASCO GU 2022 | Conference coverage | Video

Simon Crabb and Petros Grivas share their highlights from ASCO GU

What were the highlights of the ASCO GU meeting? Watch this expert interview with Simon Crabb and Petros Grivas to hear their thoughts and opinions on the work presented.

25-02-2022 | ASCO GU 2022 | Conference coverage | Video

Neoadjuvant avelumab plus axitinib active in high-risk RCC

Axel Bex outlines the reasoning behind the choice of tumor response as the primary endpoint for the NeoAvAx study of avelumab plus axitinib in the neoadjuvant high-risk renal cell carcinoma setting, and discusses the next steps.

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Mapping the impact of COVID-19 on genitourinary cancers

Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic.

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Support for continuing enzalutamide after mCRPC progression

Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant prostate cancer in the context of the current treatment landscape, and outlines unanswered questions.

23-02-2022 | ASCO GU 2022 | Conference coverage | Video

First-line avelumab investigated in cisplatin-unfit advanced UC patients

Roberto Iacovelli presents the ARIES trial of frontline avelumab in patients with PD-L1-positive advanced urothelial cancer who are unable to tolerate cisplatin.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

23-02-2022 | ASCO GU 2022 | Conference coverage | Video

MAGNITUDE shows benefit of add-on niraparib for mutated mCRPC

Gerhardt Attard tells us why he is excited about the results of the MAGNITUDE trial evaluating the upfront addition of niraparib to abiraterone acetate in men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

22-02-2022 | ASCO GU 2022 | Conference coverage | Video

Add-on PARP inhibition in metastatic CRPC: PROpel and MAGNITUDE

David VanderWeele comments on the PROpel and MAGNITUDE trials investigating the addition of a PARP inhibitor to abiraterone in men with metastatic castration-resistant prostate cancer, focusing on the differences between the studies and the unanswered questions.

21-02-2022 | ASCO GU 2022 | Conference coverage | Video

Potential of sacituzumab govitecan plus pembrolizumab demonstrated in mUC patients

Petros Grivas explains why sacituzumab govitecan plus pembrolizumab – investigated in cohort 3 of the TROPHY-U-01 study comprising metastatic urothelial cancer patients with progression after platinum-based treatment – is not ready for prime time, but merits further investigation in this setting.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany


18-02-2022 | ASCO GU 2022 | Conference coverage | Video

ATLANTIS points to maintenance benefit of rucaparib in mUC

Simon Crabb outlines the final results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic urothelial cancer, and discusses them in light of the recent JAVELIN Bladder 100 and ATLAS trials.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  • » This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

ASCO GU 2022 research news

18-02-2022 | ASCO GU 2022 | Conference coverage | News

Darolutamide add-on prolongs survival in mHSPC

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox